GR3031873T3 - Substituted thiazolidinedione derivatives. - Google Patents

Substituted thiazolidinedione derivatives.

Info

Publication number
GR3031873T3
GR3031873T3 GR990402958T GR990402958T GR3031873T3 GR 3031873 T3 GR3031873 T3 GR 3031873T3 GR 990402958 T GR990402958 T GR 990402958T GR 990402958 T GR990402958 T GR 990402958T GR 3031873 T3 GR3031873 T3 GR 3031873T3
Authority
GR
Greece
Prior art keywords
substituted
group
compounds
unsubstituted
pharmaceutically acceptable
Prior art date
Application number
GR990402958T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3031873(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB878720825A external-priority patent/GB8720825D0/en
Priority claimed from GB878727987A external-priority patent/GB8727987D0/en
Priority claimed from GB888802454A external-priority patent/GB8802454D0/en
Application filed filed Critical
Publication of GR3031873T3 publication Critical patent/GR3031873T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
GR990402958T 1987-09-04 1999-11-18 Substituted thiazolidinedione derivatives. GR3031873T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878720825A GB8720825D0 (en) 1987-09-04 1987-09-04 Compounds
GB878727987A GB8727987D0 (en) 1987-11-30 1987-11-30 Novel compounds
GB888802454A GB8802454D0 (en) 1988-02-04 1988-02-04 Compounds

Publications (1)

Publication Number Publication Date
GR3031873T3 true GR3031873T3 (en) 2000-02-29

Family

ID=27263577

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402958T GR3031873T3 (en) 1987-09-04 1999-11-18 Substituted thiazolidinedione derivatives.

Country Status (18)

Country Link
US (1) US5002953A (enExample)
EP (2) EP0306228B1 (enExample)
JP (6) JP2614497B2 (enExample)
KR (1) KR0164207B1 (enExample)
AT (1) ATE186724T1 (enExample)
AU (1) AU611938B2 (enExample)
CA (1) CA1328452C (enExample)
CZ (1) CZ391691A3 (enExample)
DE (2) DE3856378T2 (enExample)
DK (2) DK175176B1 (enExample)
ES (1) ES2137915T3 (enExample)
GR (1) GR3031873T3 (enExample)
IE (1) IE20000683A1 (enExample)
LU (1) LU90711I2 (enExample)
NL (1) NL300034I2 (enExample)
NZ (1) NZ226027A (enExample)
PT (1) PT88410B (enExample)
SG (1) SG59988A1 (enExample)

Families Citing this family (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919417D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5053420A (en) * 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9017218D0 (en) * 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
DE69214467T3 (de) * 1991-01-10 2000-09-28 Transcend Therapeutics, Inc. Verwendung von L-2-oxo Thiazolidin-4-carboxylat zur Behandlung von Atemnotsyndrom
US5747459A (en) * 1991-02-04 1998-05-05 Nestec, Ltd. Method for insuring adequate intracellular glutathione in tissue
JP3053490B2 (ja) * 1991-02-25 2000-06-19 杏林製薬株式会社 チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
EP0635007A1 (en) * 1992-04-10 1995-01-25 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
US5589492A (en) * 1992-04-10 1996-12-31 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of Type-II diabetes
US5430045A (en) * 1992-04-23 1995-07-04 Free Radical Sciences, Inc. Method of reducing or preventing bone marrow hypoplasia
EP0648212B1 (en) * 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
DK0590793T3 (da) * 1992-08-31 2000-01-31 Sankyo Co Oxazolidin-derivater med anti-diabetiske og anti-obesitas-egenskaber, fremstilling deraf samt deres terapeutiske anvendelse
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
HU224548B1 (hu) * 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
GB9311661D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) * 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
GB9315148D0 (en) * 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
WO1995007694A1 (en) * 1993-09-15 1995-03-23 Sankyo Company, Limited Use of thiazolidinediones to prevent or delay onset of niddm
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5447712A (en) * 1993-12-09 1995-09-05 Free Radical Sciences Method of reducing cyclophosphamide induced hemorrhagic cystitis
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
RU2114844C1 (ru) * 1994-04-11 1998-07-10 Санкио Компани Лимитед Производные тиозолидиндиона или их фармацевтически приемлемые соли, фармацевтическая композиция на их основе и способ лечения или профилактики заболеваний
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
CZ261095A3 (en) 1994-10-07 1996-04-17 Sankyo Co Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
US5436373A (en) * 1994-10-26 1995-07-25 Elf Atochem North America, Inc. Process for the preparation of N-benzyl-N-organoaminoalkanol
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
US5847008A (en) * 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US6090836A (en) * 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US6020382A (en) * 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
EP0916651B1 (en) * 1996-04-04 2003-10-15 Sankyo Company, Limited Phenylalkylcarboxylic acid derivatives
EP0801063B1 (en) * 1996-04-09 2003-01-15 Dr. Reddy's Laboratories Ltd. Thiazolidinedione derivatives having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889025A (en) * 1996-05-06 1999-03-30 Reddy's Research Foundation Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
WO1997043283A1 (de) * 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neues verfahren zur herstellung von troglitazone
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP0923580A1 (en) * 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US6160000A (en) * 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
AU774839B2 (en) * 1997-02-18 2004-07-08 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
UY24886A1 (es) * 1997-02-18 2001-08-27 Smithkline Beecham Plc Tiazolidindiona
DE69838789T2 (de) * 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte Verfahren zur behandlung oder prävention der alzheimerischen krankheit
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6313113B1 (en) * 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
SI0996444T1 (sl) * 1997-06-18 2007-08-31 Smithkline Beecham Plc Zdravljenje diabetesa s tiazolidindionom in metforminom
AP1600A (en) 1997-06-18 2006-04-28 Smithkline Beecham Plc Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
CA2305808A1 (en) 1997-10-02 1999-04-15 Sankyo Company Limited Amidocarboxylic acid derivatives
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9723295D0 (en) * 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
JP4391597B2 (ja) * 1997-12-02 2009-12-24 ドクター・レディーズ・ラボラトリーズ・リミテッド 抗糖尿病性、低脂質性及び抗高血圧性を有するチアゾリンジオンとオキサゾリジンジオン誘導体
ATE269862T1 (de) * 1997-12-02 2004-07-15 Reddys Lab Ltd Dr Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
WO1999030739A1 (en) * 1997-12-16 1999-06-24 Sankyo Company, Limited Leukemia remedy
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AU4956699A (en) 1998-06-19 2000-01-05 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP2002521326A (ja) * 1998-07-21 2002-07-16 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アポトーシスを低減するためのグルコース取り込み増強剤の使用
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
IN187716B (enExample) * 1998-09-14 2002-06-15 Reddy Research Foundation
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
AR023700A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
PT1131070E (pt) * 1998-11-12 2008-11-19 Smithkline Beecham Plc Composição farmacêutica para libertação modificada de um sensibilizador à insulina e de outro agente antidiabético
AU1740900A (en) * 1998-11-20 2000-06-13 Genentech Inc. Method of inhibiting angiogenesis
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2000043006A1 (en) * 1999-01-19 2000-07-27 Sankyo Company, Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
AR023568A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una forma polimorfica de sal de acido maleico derivado de tiazolidina-2,4-diona
TR200103060T2 (tr) * 1999-04-23 2002-05-21 Smithkline Beecham P. L. C. Yeni farmasötik maddeler
YU75301A (sh) 1999-04-23 2004-07-15 Smithkline Beecham P.L.C. Polimorfni oblik soli maleinske kiseline i 5-(4-(2-(n-metil- n-(2-piridil)amino)etoksi)benzil)-tiazolidin-2,4-diona
EP1180520B1 (en) 1999-04-28 2007-06-20 Institute of Medicinal Molecular Design, Inc. Pyrimidine carboxylic acid derivatives
GB9913782D0 (en) * 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
EP1194147B1 (en) * 1999-06-18 2007-01-10 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
CZ2002531A3 (cs) * 1999-08-17 2002-07-17 Smithkline Beecham P. L. C. Farmaceutické prostředky obsahující thiazolidindionové deriváty a způsob jejich přípravy
US6878749B2 (en) 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
ES2156574B1 (es) * 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
WO2001040192A1 (en) 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
DK1741447T3 (da) 2000-01-21 2013-12-09 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2001090356A1 (fr) * 2000-05-25 2001-11-29 Yamanouchi Pharmaceutical Co., Ltd. Promoteur de pgc-1 humain
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7078397B2 (en) 2000-06-19 2006-07-18 Smithkline Beecham Corporation Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
AU2001294673A1 (en) 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
SK3752003A3 (sk) * 2000-09-26 2005-03-04 Dr. Reddy's Laboratories Limited Polymorfné formy 5-[4[2-[N-metyl-N-(2- pyridyl)aminol]etoxy]benzyl]tiazolidín-2,4-dión maleátu a spôsob ich prípravy
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0029125D0 (en) * 2000-11-29 2001-01-10 Specialistkliniken I Varberg H Novel treatment
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
ATE337313T1 (de) * 2000-12-22 2006-09-15 Smithkline Beecham Plc 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
WO2002051441A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
ES2174748B1 (es) * 2001-01-31 2003-09-16 Vita Lab Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
ATE423559T1 (de) * 2001-04-04 2009-03-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
US20060047000A1 (en) * 2001-04-24 2006-03-02 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
CZ20033415A3 (cs) * 2001-05-29 2004-06-16 Kyoto Pharmaceutical Industries, Ltd. Nové heterocyklické deriváty a jejich lékařské použití
US7557123B2 (en) * 2001-05-29 2009-07-07 Kyoto Pharmaceutical Industries, Ltd. Heterocyclic compound and medicinal use thereof
JP4152641B2 (ja) * 2001-08-07 2008-09-17 クラシエ製薬株式会社 チアゾリジン誘導体の副作用軽減剤
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
WO2003050116A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
US6992191B2 (en) * 2001-12-20 2006-01-31 Teva Pharmaceutical Industries, Ltd. Hydrogenation of precursors to thiazolidinedione antihyperglycemics
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003053962A1 (en) * 2001-12-20 2003-07-03 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
KR100450700B1 (ko) * 2002-03-22 2004-10-01 주식회사종근당 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
ATE321039T1 (de) * 2002-04-29 2006-04-15 Teva Pharma Verfahren zur herstellung von losartan und losartan-kaliumsalz
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2004089945A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Rosiglitazone derivatives as antidiabetic agents
US20050004179A1 (en) * 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
JPWO2004106542A1 (ja) * 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
AP2501A (en) * 2003-05-30 2012-10-22 Ranbaxy Lab Ltd Substituted pyrrole derivatives
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
WO2005023803A1 (en) * 2003-09-10 2005-03-17 Biocon Limited Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione
JP5140881B2 (ja) * 2003-09-17 2013-02-13 要 川杉 医薬組成物
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
US20050163837A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone formulations
WO2005073227A2 (en) * 2004-01-28 2005-08-11 Usv Limited A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
CN102127057A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
KR20070011329A (ko) * 2004-03-29 2007-01-24 상꾜 가부시키가이샤 인슐린 저항성 개선제를 함유하는 당뇨병 치료제
GB2413795A (en) * 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
CA2566352A1 (en) * 2004-05-12 2005-11-17 Medichem S.A. Process for the preparation of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
TW200608967A (en) * 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
CZ297266B6 (cs) * 2004-09-10 2006-10-11 Zentiva, A. S. Zpusob prípravy rosiglitazonu
CZ297347B6 (cs) * 2004-09-21 2006-11-15 Zentiva, A. S. Zpusob prípravy rosiglitazonu
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
US20060122232A1 (en) * 2004-12-06 2006-06-08 Development Center For Biotechnology 4-Hydroxyfuroic acid derivatives
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
US20070269486A1 (en) * 2005-03-14 2007-11-22 Conor Medsystems, Llc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
FR2887444A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
FR2887442A1 (fr) * 2005-06-28 2006-12-29 Oreal Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
CN101272805A (zh) * 2005-07-12 2008-09-24 第一三共株式会社 包含PPARγ激动剂的药物组合物
AU2006290205B2 (en) * 2005-09-14 2012-12-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CA2622642C (en) * 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
TW200730173A (en) * 2005-12-16 2007-08-16 Sankyo Co Pharmaceutical composition enhancing production of adiponectin
CA2645189A1 (en) * 2006-03-08 2008-01-24 Medichem, S.A. Process for preparation of intermediates of rosiglitazone, rosiglitazone and new polymorphic forms thereof
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
JP2009531456A (ja) * 2006-03-28 2009-09-03 武田薬品工業株式会社 （ｒ）−３−アミノピペリジン二塩酸塩の調製
CN101410105A (zh) * 2006-03-31 2009-04-15 维尔斯达医疗公司 代谢紊乱的组合治疗
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20070293546A1 (en) * 2006-06-15 2007-12-20 Srinivasula Reddy Maddula Preparation of rosiglitazone and its salts
HUP0600517A3 (en) * 2006-06-23 2008-10-28 Richter Gedeon Nyrt Process for the production of benzylidene-rosiglitazone base
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
AR063469A1 (es) * 2006-07-14 2009-01-28 Ranbaxy Lab Ltd Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
CN103211819A (zh) * 2006-09-13 2013-07-24 武田药品工业株式会社 2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2114404A4 (en) 2006-12-21 2010-03-03 Alphapharm Pty Ltd COMPOUND AND PHARMACEUTICAL COMPOSITION
US20080176905A1 (en) * 2007-01-22 2008-07-24 Santiago Ini Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
WO2008096829A1 (ja) 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ３環系化合物
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
ES2550479T3 (es) * 2007-04-05 2015-11-10 Daiichi Sankyo Company, Limited Derivados de heteroarilo bicíclico condensado
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
CN101772513B (zh) 2007-06-04 2013-11-13 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
RS53237B (sr) 2007-07-26 2014-08-29 Amgen Inc Modifikovani enzimi lecitin-holesterol aciltransferaze
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8486980B2 (en) 2008-08-06 2013-07-16 Kyowa Hakko Kirin Co., Ltd. Tricyclic compound
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
PT2324126E (pt) 2008-08-12 2014-06-02 Zinfandel Pharmaceuticals Inc Método de identificação de factores de risco da doença de alzheimer
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
HUP0800755A2 (en) 2008-12-11 2010-09-28 Richter Gedeon Nyrt Crystalline forms of rosiglitazone
SG172469A1 (en) 2009-03-05 2011-08-29 Daiichi Sankyo Co Ltd Pyridine derivative
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US20140088027A1 (en) 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
CA2810361A1 (en) 2010-09-07 2012-03-15 Daiichi Sankyo Company, Limited Process for preparing benzoic acid esters
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
US8969345B2 (en) 2011-08-03 2015-03-03 Kyowa Hakko Kirin Co., Ltd. Dibenzooxepin derivative
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
JP6635655B2 (ja) 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
WO2014068397A1 (en) 2012-11-05 2014-05-08 Commissariat A L'energie Atomique Et Aux Energies Atlternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
HRP20240805T1 (hr) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe
WO2015054500A2 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
AU2014347668A1 (en) 2013-11-05 2016-05-19 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
EP3412302B1 (en) 2014-10-24 2021-05-12 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
WO2018130679A1 (en) 2017-01-16 2018-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
GR1010570B (el) * 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
SG59988A1 (en) * 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives

Also Published As

Publication number Publication date
DK490288A (da) 1989-03-05
DK490288D0 (da) 1988-09-02
CZ391691A3 (en) 1993-03-17
LU90711I2 (fr) 2001-03-05
NZ226027A (en) 1992-03-26
AU611938B2 (en) 1991-06-27
JPH10194971A (ja) 1998-07-28
EP0306228B1 (en) 1999-11-17
JP2817840B2 (ja) 1998-10-30
SG59988A1 (en) 1999-02-22
AU2173888A (en) 1989-03-09
ATE186724T1 (de) 1999-12-15
PT88410A (pt) 1989-07-31
CA1328452C (en) 1994-04-12
NL300034I2 (nl) 2001-05-01
JP2614497B2 (ja) 1997-05-28
JPH09183726A (ja) 1997-07-15
DK175176B1 (da) 2004-06-21
DE3856378D1 (de) 1999-12-23
KR0164207B1 (ko) 1999-01-15
EP0842925A1 (en) 1998-05-20
JP2837139B2 (ja) 1998-12-14
EP0306228A1 (en) 1989-03-08
DE3856378T2 (de) 2000-05-11
DE10199003I2 (enExample) 2003-09-18
JPH01131169A (ja) 1989-05-24
JPH09183771A (ja) 1997-07-15
NL300034I1 (nl) 2001-03-01
KR890005095A (ko) 1989-05-11
IE20000683A1 (en) 2002-07-24
PT88410B (pt) 1992-10-30
DE10199003I1 (de) 2003-06-12
US5002953A (en) 1991-03-26
JPH09183772A (ja) 1997-07-15
JPH10194970A (ja) 1998-07-28
DK200001556A (da) 2000-10-18
HK1011029A1 (en) 1999-07-02
ES2137915T3 (es) 2000-01-01

Similar Documents

Publication Publication Date Title
GR3031873T3 (en) Substituted thiazolidinedione derivatives.
ZA906708B (en) Thiazolidinedione derivatives
ZA906709B (en) Thiazolidinedione derivatives
HU9500006D0 (en) Heterocyclic compounds as pharmaceutical
TW385309B (en) Novel thiazolidinedione antidiabetic agents
EP0356214A3 (en) Thiazolidine dione derivatives
GB9308487D0 (en) Novel compounds
NZ214787A (en) Arylcyclobutylalkylamines and pharmaceutical compositions
NZ231380A (en) Xanthine derivatives and pharmaceutical compositions
IL85768A (en) Benzoxazine derivatives, their preparation and pharmaceutical compositions containing them
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.